HS
CMPX icon

HighVista Strategies’s Compass Therapeutics CMPX Stock Holding History

HighVista Strategies’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-245,532
Closed -$1.32M – 167
2025
Q4 		$1.32M Buy
+245,532
New +$1.13M 0.34% 78

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HighVista Strategies's CMPX Position: Q1 2026 in Review

HighVista Strategies sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 245,532 shares — an estimated $1.32M sold.

HighVista Strategies first reported a position in CMPX in Q4 2025 and held it in 1 quarter. The position peaked at $1.32M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • HighVista Strategies reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HighVista Strategies sold 245,532 Compass Therapeutics shares in Q1 2026, an estimated $1.32M.
  • HighVista Strategies first reported a position in Compass Therapeutics in Q4 2025 and held it in 1 quarter.
  • HighVista Strategies's Compass Therapeutics position peaked at $1.32M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.